Condition
DLBCL, Nos Genetic Subtypes clinical trials and research
As of November 12, 2026, Find a Trial lists 2 DLBCL, Nos Genetic Subtypes clinical trials that are recruiting, at sites in 2 countries (most in China (1), Australia (1)). By phase: Phase 1 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
C402 CD19 CAR treatment for relapsed or refractory large B‑cell lymphoma
We will try an autologous CD19-directed CAR‑T therapy (C402) in adults with relapsed or refractory CD19‑positive large B‑cell lymphoma to see if it is safe and tolerable.
-
Combination therapy with Epcoritamab for relapsed aggressive B-cell lymphoma
This study is testing if adding Epcoritamab to chemotherapy helps people with relapsed aggressive B-cell lymphoma get better before a stem cell transplant and live longer without the disease coming back.
Related topics
Quick answers
How many DLBCL, Nos Genetic Subtypes clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (1 trial), Australia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.